Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib

Blood Cancer J. 2015 Oct 2;5(10):e351. doi: 10.1038/bcj.2015.77.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dasatinib / administration & dosage
  • Female
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Janus Kinase 2 / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Middle Aged
  • Nitriles
  • Polycythemia Vera / complications
  • Polycythemia Vera / drug therapy*
  • Polycythemia Vera / genetics
  • Pyrazoles / administration & dosage
  • Pyrimidines

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Fusion Proteins, bcr-abl
  • JAK2 protein, human
  • Janus Kinase 2
  • Dasatinib